Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data (CROSBI ID 151171)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Locatelli, F. ; Čović, Adrian ; Macdougall, I.C. ; Wiecek, A. ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data // JN. Journal of nephrology, 21 (2008), 4; 592-602

Podaci o odgovornosti

Locatelli, F. ; Čović, Adrian ; Macdougall, I.C. ; Wiecek, A.

engleski

ORAMA : a study to investigate EBPG impact on renal anaemia – design and baseline data

Background: It is of paramount importance not only to publish anaemia management guidelines for chronic kidney disease (CKD) but also to verify their implementation in clinical practice. The Optimal Renal Anaemia Management Assessment (ORAMA) is the first European study investigating the impact of adherence to the 2004 revised European Best Practice Guidelines (EBPG) and its impact on patient outcomes. Participating centres were randomised into 2 groups: group A with, and group B without, access to an EBPG-based computerised clinical decision support (CDS) system after baseline. Patients with stage 2-5 CKD either anaemic (haemoglobin [Hb] <11 g/dL) or treated with erythropoiesis-stimulating agents (ESAs) and/or iron supplementation were enrolled. Primary end points are based on achievement of anaemia-related guideline targets. Here, baseline data are reported descriptively. Fifty-three centres in 8 countries included 739 patients, 81% of whom have received dialysis. Mean baseline Hb was 11.2 g/dL, and 52% of all patients met the EBPG target of >11 g/dL Hb at baseline. However, only 37% of patients had their Hb values >11 g/dL throughout a 3-month prestudy period. Serum ferritin and transferrin saturation were above the guideline target in circa 80% of patients. The vast majority of patients (96%) received ESA therapy at baseline. In line with findings from previous studies ORAMA baseline data show that achievement of EBPG is suboptimal across European countries. Final results promise an insight into the impact of guideline-based CDS tools on clinical practice and target attainment.

anaemia management guidelines; Chronic kidney disease; Clinical decision support system; Erythropoiesis-stimulating agents; European best practice guidelines; ORAMA; Renal anaemia; Recombinant-human-erythropoietin; Chronic kidney-disease; Hemodialysis-patients; Practice guidelines; Dialysis outcomes; Practice patterns; Management; Mortality; Quality; Performance

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

21 (4)

2008.

592-602

objavljeno

1121-8428

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost